Encoded Therapeutics reported Phase 1/2 Dravet syndrome gene‑therapy data showing a 78% reduction in seizures linked to ETX101, moving the program toward a pivotal study next year. The company said the magnitude of seizure reduction supports a streamlined path into a registrational trial. Encoded plans to discuss the dataset with regulators to finalize pivotal trial design. The results underscore the advancing field of in‑vivo and targeted gene therapies for severe pediatric epilepsies and will intensify competition and investor attention in neurogenetic modalities.